Company intelligence / Profile preview
Grid Therapeutics
Durham, North Carolina, United Statesgridtherapeutics.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Phase 2
01
Overview
Currently conducting a Phase 2 investigator-sponsored trial of GT103 in combination with Merck's pembrolizumab in patients with advanced NSCLC. Previously enrolled patients in a first-in-man Phase 1 clinical trial in refractory NSCLC patients[2][4].
- Therapeutic areas
- Oncology
- Modalities
- Human-derived antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Merck (for combination trial with pembrolizumab)[4]
Beyond the preview
Go deeper on Grid Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Grid Therapeutics.